Bacteriology

Techcyte Closes $21 Million Funding Round

Retrieved on: 
Thursday, August 19, 2021
Health, Data Management, Veterinary, Technology, Software, HIPAA, Zoetis, Efficiency, CE, Animal, ARUP Laboratories, Trade, Hospital, Pathology, Solution, Laboratory, CEO, Bacteriology, Hematology, FDA, Commercial, FNA Mapping, Technology, Inc., Medical imaging

Techcyte Inc. closed a $21 million funding round to accelerate commercialization of its digital clinical pathology platform.

Key Points: 
  • Techcyte Inc. closed a $21 million funding round to accelerate commercialization of its digital clinical pathology platform.
  • The investors in this round include Zoetis, ARUP Laboratories and investors from previous rounds.
  • Ben Cahoon, the CEO of Techcyte, said, Our relationship with Zoetis has been incredible as weve revolutionized diagnostics for veterinary clinics.
  • With offices in Orem, Utah and Luxembourg, Techcyte, Inc. was founded in 2013 with a mission to digitize and automate diagnostics.

Karius receives New York State permit for its liquid biopsy test to detect infectious diseases

Retrieved on: 
Tuesday, August 17, 2021
Bloodstream infections, Twitter, Death, Cancer, Parasitology, Laboratory developed test, Infection, LDT, Parasitism, Bacteria, Fungus, Liquid biopsy, DNA, DNA virus, Health, CA, Immunodeficiency, Hospital, Multimedia, CAP, Mycology, Patient, CEO, Bacteriology, NYS, CLEP, Virology, Pharmaceutical industry, Vaccine

REDWOOD CITY, Calif., Aug. 17, 2021 /PRNewswire/ -- Karius, the world leader in liquid biopsy for infectious diseases, has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 17, 2021 /PRNewswire/ -- Karius, the world leader in liquid biopsy for infectious diseases, has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.
  • The Karius Test is commercially available from a single CLIA-certified and CAP-accredited laboratory in Redwood City, CA, as a Laboratory Developed Test (LDT).
  • The decision by CLEP is a first-in-class approval of a clinical metagenomics test for the detection of infectious diseases, and will expand patient access to critical testing in New York.
  • The Karius Test is primarily used to detect specific causative pathogens in immunocompromised patients and other specific clinical syndromes.

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Bacteriology, Biology, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biofilm, Antimicrobial

The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Bacteriology, Biology, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biofilm, Antimicrobial

KEELE, England, Aug. 4, 2021 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the Musculoskeletal Infection Society's 31st Annual Open Scientific Meeting, which is being held in Fort Lauderdale 6-7 August 2021. The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

HempFusion Closes Acquisition of Apothecanna

Retrieved on: 
Tuesday, August 3, 2021
MEN, General Health, Other Retail, Tobacco, Consumer, Convenience store, Retail, Public relations, Investor relations, Women, Communications, Alternative medicine, Health, Bacteriology, Digestive system, Probiotic

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (HempFusion or the Company), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce that it has completed its previously announced acquisition of APCNA Holdings LLC (Apothecanna) (the Transaction).

Key Points: 
  • HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (HempFusion or the Company), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce that it has completed its previously announced acquisition of APCNA Holdings LLC (Apothecanna) (the Transaction).
  • With the recent Sagely Naturals acquisition and now closing of the Apothecanna acquisition, HempFusion is in its strongest position to date.
  • The Transaction was completed pursuant to the terms of the unit purchase agreement dated May 14, 2021, as amended (the Purchase Agreement) among HempFusion, Apothecanna, all holders of Apothecanna interests (the Sellers) and Jeff Henretig, as representative of the Sellers.
  • HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations.

OMNi-BiOTiC® Stress Release Awarded Probiotic of the Year by NutraIngredients USA

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Magazines, Digestive system, Bacteriology, Sympathetic nervous system, Biotic, Probiotic, Klaus Kleinfeld, Omni, Stress

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Omni-Biotic Stress Release is named "Product of the Year" in the probiotic category at the NutraIngredients USA Awards 2021.

Key Points: 
  • NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Omni-Biotic Stress Release is named "Product of the Year" in the probiotic category at the NutraIngredients USA Awards 2021.
  • CEO of Allergosan USA, Klaus Kleinfeld, adds: "It's an honor to have Omni-Biotic Stress Release recognized as the Probiotic of the Year.
  • Studied in controlled clinical trials, the supplementation of Omni-Biotic Stress Release showed improved mood , memory, cognition, stress response , and gastro-intestinal comfort .
  • The company is dedicated to delivering targeted probiotic blends for specific indications including stress, immunity, liver detox and more.

Ancilia Biosciences Awarded NSF Grant to Advance Platform Designed to Address Overlooked Obstacle to Success for Microbiome Therapeutics

Retrieved on: 
Tuesday, August 3, 2021
Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Bacteriophage, Biology, Gut microbiota, Organisms, Articles, Microbiome

We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.

Key Points: 
  • We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
  • There is evidence that phages are associated with disease and that they may also compromise the efficacy of LBPs.
  • We are delighted that the NSF sees potential in our technology and is supporting further development of our platform."
  • Ancilia Biosciences ( www.anciliabio.com) is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome and treat disease.

BGN Technologies Introduces New Method for Identifying Bacteria and Their Susceptibility to Antibiotics

Retrieved on: 
Tuesday, August 3, 2021
Bacteriology, Urinary tract infection, Bacteria, Technology transfer, Branches of biology, Health

The method has been tested on over 1,000 urine samples and was able to discriminate between bacterial species with approximately 97% accuracy and determine bacterial susceptibility to various antibiotics with approximately 85% accuracy.

Key Points: 
  • The method has been tested on over 1,000 urine samples and was able to discriminate between bacterial species with approximately 97% accuracy and determine bacterial susceptibility to various antibiotics with approximately 85% accuracy.
  • BGN Technologies, the technology transfer companyof BGU, has filed for patent protection and is now seeking a strategic partner for the further development and commercialization of this promising technology.
  • "This method for the identification of bacterial pathogens in UTI patients is an important and long-awaited solution for the management of UTI," said Josh Peleg, CEO of BGN Technologies.
  • BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Omadacycline, Mycobacterium, Tuberculosis

These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Key Points: 
  • These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.
  • Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Microbiology, Infectious diseases, Acid-fast bacilli, Bacterial diseases, Bacteriology, Infectious causes of cancer, Healthcare-associated infections, Nontuberculous mycobacteria, Mycobacterium, Omadacycline, Tuberculosis

Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.

Key Points: 
  • Domestic investors wishing to participate in the call should dial: 855-327-6837 and international investors should dial: 631-891-4304.
  • Paratek Pharmaceuticals, Inc.is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government andmilitary use.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.
  • Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease, caused by Mycobacterium abscessus Complex (MABc) with NUZYRA.